Skip to main content

Advertisement

Log in

Female sexual dysfunction is being medicalized by the pharmaceutical industry: Pro

  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Medicalization is a key process of social change and social influence. It occurs not merely because of scientific developments, but because biomedical claims are actively promoted by those with professional and economic interests in expanding medical domains. This article examines how women’s sexual health is being medicalized by the pharmaceutical industry, and why that poorly serves women’s real sexual lives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Conrad P: Medicalization and social control. Ann Rev Sociol 1992, 18:209–232.

    Article  Google Scholar 

  2. Riessman CK: Women and medicalization: a new perspective. Soc Policy 1983, 14(1):3–18.

    PubMed  CAS  Google Scholar 

  3. Tiefer L: The medicalization of sexuality: conceptual, normative, and professional issues. Annu Rev Sex Res 1996, 7:252–282.

    Google Scholar 

  4. Daniluk JC: Women’s Sexuality Across the Life Span. New York: Guilford Press; 1998.

    Google Scholar 

  5. Tiefer L: Commentary on the status of sex research: feminism, sexuality, and sexology. J Psychol Human Sex 1991, 4:5–42.

    Article  Google Scholar 

  6. Tiefer L: The emerging global discourse of sexual rights. J Sex Marital Ther 2002, 28:439–444.

    Article  PubMed  Google Scholar 

  7. The Surgeon General’s Call to Action to Promote Sexual Health and Responsible Sexual Behavior. http://www.surgeongeneral. gov/library/sexualhealth/default.htm. 2001.

  8. Giami A: Sexual health: the emergence, development, and diversity of a concept. Ann Rev Sex Res 2002, 13:1–35.

    Google Scholar 

  9. Berman JR, Berman L, Goldstein I: Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. Urology 1998, 54:385–391.

    Article  Google Scholar 

  10. Basson R, Berman J, Burnett A, et al.: Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000, 163:888–893.

    Article  PubMed  CAS  Google Scholar 

  11. Tiefer L: Arriving at a "new view" of women’s sexual problems: background, theory, and activism. In A New View of Women’s Sexual Problems. Edited by Kaschak L, Tiefer L. Binghamton, NY: Haworth; 2001:63–98.

    Google Scholar 

  12. Moynihan R: The making of a disease: female sexual dysfunction. BMJ 2003, 326:45–47.

    Article  PubMed  Google Scholar 

  13. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States. JAMA 1999, 281:537–544.

    Article  PubMed  CAS  Google Scholar 

  14. Laumann EO, Gagnon JH, Michael RT, Michaels S: The Social Organization of Sexuality: Sexual Practices in the United States. Chicago: University of Chicago Press; 1994.

    Google Scholar 

  15. Grady D: Sure, we’ve got a pill for that. The New York Times. February 14, 1999; section 4:1, 5.

  16. National Women’s Health Network: The Truth About Hormone Replacement Therapy. New York: Prima Publishing; 2002.

    Google Scholar 

  17. Coney S: The Menopause Industry. Alameda, CA: Hunter House; 1994.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tiefer, L. Female sexual dysfunction is being medicalized by the pharmaceutical industry: Pro. Curr sex health rep 1, 117–119 (2004). https://doi.org/10.1007/s11930-004-0028-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-004-0028-x

Keywords

Navigation